PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME
The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and methods of using same to treat a variety of conditions and disorders.
1 . A method of treating a skin disease or disorder in a subject in need thereof, the method comprising orally administering to the subject a pharmaceutical composition comprising DGLA or a derivative thereof.
2 . The method of claim 1 , wherein the composition is administered to the subject in an amount sufficient to provide about 1 g to about 4 g of DGLA or a derivative thereof per day.
3 . The method of claim 1 , wherein the DGLA or derivative thereof is administered to the subject for a period of at least about 2 weeks, at least about 4 weeks or at least about 8 weeks.
4 . The method of claim 1 , wherein the subject is a pediatric subject.
5 . The method of claim 1 , wherein the subject has a low eosinophil cell count.
6 . The method of claim 5 , wherein the low eosinophil cell count is determined based on a reference level.
7 . A method of reducing at least one of an investigator global assessment level, eczema area and severity index (EASI) score, a percentage of area of an anatomical site affected by atopic dermatitis, Scoring atopic dermatitis (SCORAD), body surface area affected by atopic dermatitis, or Visual Analog Scale (VAS) pruritus score in a subject in need thereof, the method comprising orally administering to the subject up to 4 g per day of DGLA or derivative thereof.
8 . The method of claim 7 , wherein about 0.2 to about 3 g of DGLA or derivative thereof is orally administered to the subject per day.
9 . The method of claim 7 , wherein about 0.5 g, about 1 g or about 2 g of DGLA or derivative thereof is orally administered to the subject per day.
10 . The method of claim 7 , wherein less than 1 g of DGLA or derivative thereof is orally administered to the subject per day.
11 . The method of claim 7 , wherein the subject is a pediatric subject.
12 . The method of claim 7 , wherein the DGLA or derivative thereof is administered to the subject for a period of at least about 2 weeks, at least about 4 weeks or at least about 8 weeks.
13 . The method of claim 7 , wherein the pharmaceutical composition comprises DGLA or a derivative thereof in a liquid or semi-liquid format.
14 . The method of claim 7 , wherein the subject is determined to have a low baseline eosinophil count as compared to a reference level.